Behavioral medicine

Baszucki Group Announces Columbia University's Martin Picard, PhD as Inaugural Recipient of $1.5 Million Baszucki Prize in Science

Retrieved on: 
Tuesday, March 5, 2024
SAN, Metabolism, Mental health, Doctor of Philosophy, Neuroscience, Ageing, Overalls, Neurology, Behavioral medicine, Communication, Mitochondrion, Health, Genetics, Columbia, Associate, Teaching, Medicine, Disease, DSM-IV codes, Research, Brain, Pharmaceutical industry

SAN MATEO, Calif., March 5, 2024 /PRNewswire/ -- Baszucki Group today announced that Columbia University's Martin Picard, PhD, is the first to receive the new Baszucki Prize in Science. Dr. Picard, Associate Professor of Behavioral Medicine in Psychiatry and Neurology, received the $1.5 million prize for his groundbreaking work connecting brain energetics and mitochondria to the human experience. Dr. Picard has led seminal research establishing mitochondrial psychobiology as a critical new field advancing our understanding of health and disease.

Key Points: 
  • Dr. Picard has led seminal research establishing mitochondrial psychobiology as a critical new field advancing our understanding of health and disease.
  • "Baszucki Group has been an invaluable supporter of our work and I am honored to be the first to receive this prestigious new prize," said Dr. Picard.
  • Baszucki Group's prize programs are designed to reward progress in science, medicine, and other disciplines.
  • The newly established Baszucki Prize will periodically recognize an individual who has leveraged prior Baszucki Group funding to make exceptional contributions to their field.

The Multiple Sclerosis Association of America (MSAA) Provides Resources Focused on Improving Lives Through Supportive Connections This MS Awareness Month

Retrieved on: 
Friday, March 1, 2024
Well, Mental health, Doctor of Philosophy, Month, MD, Quality of life, Behavioral medicine, Empowerment, Multiple sclerosis, Health, Blog, Character, MSAA

CHERRY HILL, N.J., March 1, 2024 /PRNewswire/ -- The Multiple Sclerosis Association of America (MSAA) proudly recognizes March as MS Awareness Month and is pleased to present the 2024 awareness campaign theme of Improving Lives Through Supportive Connections.

Key Points: 
  • CHERRY HILL, N.J., March 1, 2024 /PRNewswire/ -- The Multiple Sclerosis Association of America (MSAA) proudly recognizes March as MS Awareness Month and is pleased to present the 2024 awareness campaign theme of Improving Lives Through Supportive Connections.
  • Weekly posts on MSAA's MS Conversations blog, focusing on the theme of Improving Lives Through Supportive Connections.
  • To access information and resources provided by MSAA during MS Awareness Month, or to register for our events, please visit the MS Awareness Month hub page at https://mymsaa.org/awarenessmonth .
  • To learn more about MS Awareness Month and MSAA's scheduled activities, please contact Diana Cruz, Manager of Public Relations & Engagement at (800) 532-7667, ext.

Papa Announces Trust and Safety Advisory Board, Furthering its Mission to Become Health Care's Safest In-person Connectivity Platform

Retrieved on: 
Tuesday, February 27, 2024
Name, Ageing, Caregiver, Doctor of Philosophy, Workplace, Ambition Institute, Risk management, Child care, Behavioral medicine, Culture, Parent, Los, General counsel, Ally, Ideation, TSA, Knowledge, MVR, Transport, Nursing

MIAMI, Feb. 27, 2024 /PRNewswire/ -- Papa, an end-to-end human care network supporting social needs, today announced the creation of a Trust and Safety Advisory Board to further its overriding priority to keep members and Papa Pals safe on every visit. This milestone, along with the implementation of other major operational and product enhancements, support Papa's goal to remain the safest in-person healthcare platform on the market.

Key Points: 
  • "While over 99.9% of Papa visits go without a member-reported safety concern, even one report is too many," said Papa's Head of Trust and Safety, Jane Yu.
  • A leading expert in trust and safety for marketplace platforms, Jeremy will support Papa with trust and safety, risk management, and regulatory compliance.
  • Other board members bring cross-functional trust and safety experience, with specialties in user research, trust and safety strategy, and operations.
  • Over the past year, Papa has implemented dozens of critical initiatives to prioritize and protect the trust and safety of its Papa Pals and members.

Daré Bioscience to Present at the Sexual Medicine Society of North America (SMSNA) 24th Annual Fall Scientific Meeting

Retrieved on: 
Monday, November 13, 2023
Cream, Arousal, Behavioral medicine, International Society, Woman, Food, Medical director, Ageing, Gynaecology, Orgasm, Female sexual arousal disorder, OBGYN, FDA, CCD, Menopause, FACOG, North American Menopause Society, Obstetrics, Female, NCMP, Erectile dysfunction, NAMS, Birth control, MD

“The comprehensive Phase 2b RESPOND study data represent an important milestone in the field of female sexual dysfunction,” said Dr. Andrew Goldstein, Medical Advisor for Daré Bioscience and former President of The International Society for the Study of Women's Sexual Health (ISSWSH).

Key Points: 
  • “The comprehensive Phase 2b RESPOND study data represent an important milestone in the field of female sexual dysfunction,” said Dr. Andrew Goldstein, Medical Advisor for Daré Bioscience and former President of The International Society for the Study of Women's Sexual Health (ISSWSH).
  • Sildenafil Cream is an investigational, proprietary topical cream formulation specifically designed to be used on-demand at the time of sexual activity to increase blood flow to the genital tissue in women.
  • "These additional data from the Phase 2b RESPOND study, which demonstrated improvements in a broader population of women, underscore the meaningful potential for Sildenafil Cream in women's sexual health.
  • There is a critical unmet need for a safe, effective and ‘on demand' solution to difficulties with sexual arousal."

Jolly Good Inc. Establishes North American Subsidiary: Joint Development of Medical VR for "Apple Vision Pro" with U.S. Experts

Retrieved on: 
Wednesday, November 1, 2023
A Jolly Good Fellow (novel), Post-traumatic stress disorder, Anxiety, VR, Cognitive behavioral therapy, Johns Hopkins University, University of Oxford, Chronic pain, United States Department of Veterans Affairs, Boston University Chobanian & Avedisian School of Medicine, SCI, Veterans' affairs, QOL, Veteran, University of Bath Department of Psychology, Opioid use disorder, Research, Chūō-ku, State, Death, PTSD, Quality of life, Learning, Feel Good Inc., Psychology, Boston University School of Public Health, Teaching, Boston University, Apple, Pain, DSM-IV codes, Eye, Opioid, CBT, Cancer, Pain management, Behavioral medicine, Patient, Doctor of Philosophy, Poultry farming, Video game, Nursing, Pharmaceutical industry, Dentistry, Neuroscience

TOKYO, Nov. 1, 2023 /PRNewswire/ -- Jolly Good Inc. (Chuo-ku, Tokyo, CEO: Kensuke Joji, hereinafter referred to as Jolly Good), which develops and provides medical VR, announces that it has established a North American subsidiary with a view to further business expansion in North America.In North America, we will also focus on development for spatial computing, including "Apple Vision Pro" (*1), in both its digital therapy VR and medical education VR businesses.

Key Points: 
  • Chronic Pain Experts
    TOKYO, Nov. 1, 2023 /PRNewswire/ -- Jolly Good Inc. (Chuo-ku, Tokyo, CEO: Kensuke Joji, hereinafter referred to as Jolly Good), which develops and provides medical VR, announces that it has established a North American subsidiary with a view to further business expansion in North America.
  • In North America, we will also focus on development for spatial computing, including "Apple Vision Pro" (*1), in both its digital therapy VR and medical education VR businesses.
  • Opioid abuse and addiction are currently a major social problem in the United States, and many people who take them experience chronic pain.
  • Through this experience, we aim to provide medical education and mental illness treatment using live-action 360-degree video, which is a feature of Jolly Good.

Cingulate to Host CNS Key Opinion Leader Panel in New York City

Retrieved on: 
Tuesday, October 17, 2023
ADHD, Champions League, Precision Time Protocol Industry Profile, Patient, Associate, Psychiatry, Union League Club, Screen for child anxiety related disorders, Cingulata, Behavioral medicine, CNS, Central nervous system disease, Nightclub

The live-streamed event will be held from 10:00am-11:30am EST at the Union League Club in Midtown Manhattan, and will focus on the Company’s leading, late-stage asset CTx-1301(dexmethylphenidate), along with ADHD and anxiety-related disorders.

Key Points: 
  • The live-streamed event will be held from 10:00am-11:30am EST at the Union League Club in Midtown Manhattan, and will focus on the Company’s leading, late-stage asset CTx-1301(dexmethylphenidate), along with ADHD and anxiety-related disorders.
  • For those in the New York area who would like to attend, there will be space for approximately 25-30 guests in the club’s Grant Room.
  • Those who wish to watch the event virtually may do so through the link provided here , with the passcode 429018.
  • “The Cingulate team thanks Dr. Childress and Dr. Mattingly for their participation in this event.

OnBalance Expands Its Roster of Experts

Retrieved on: 
Tuesday, October 10, 2023
Knowledge, DBH, ATC, Senior, Philadelphia Phillies, Sport, Communication, LAT, Jack Nicklaus, Jenna, University, Milestone, Philadelphia, Senior advisor, Health, Marketing, Behavioral medicine, PALM, Knowledge-centered support, Customer success, University of Alabama, Athlete, Business development, Management, Nursing, Financial adviser, Operation

PALM BEACH GARDENS, Fla., Oct. 10, 2023 /PRNewswire/ -- OnBalance, the first-of-its-kind comprehensive mental health care and performance management platform for athletics, today announced the appointment of its inaugural board of directors and advisory board along with new members of the company's operational team.

Key Points: 
  • The board, which includes OnBalance founder and CEO, Walt Norley, is comprised of highly respected executives from industries including healthcare, athletics, consumer products, and technology.
  • "Identifying the right people to join and build OnBalance as an early-stage company is a top priority," said Walt Norley, founder and CEO of OnBalance.
  • "I am humbled to welcome such an exceptional group of professionals to the OnBalance team.
  • OnBalance welcomes the following members to the team:
    Mike Todd, Chief Operating Officer – Mike joins OnBalance with more than 18 years of private equity experience.

Lark Health Expands Weight Management Program to Support Guided GLP-1 Care Delivery

Retrieved on: 
Thursday, September 28, 2023
Obesity, Education, Sleep, Centers for Disease Control and Prevention, Quality of life, Medicine, Annals of Behavioral Medicine, DPP, Genolier Swiss Medical Network SA, Research, Practice, Certification, Lark, CDC, Digital technology, Amwell, Patient, Lark Health, Healthy Weight Commitment Foundation, Chief medical informatics officer, Entrepreneurship, Behavioral medicine, Ecosystem, Independent Healthcare Providers Network, Pharmaceutical industry, Medical device

MOUNTAIN VIEW, Calif., Sept. 28, 2023 /PRNewswire/ -- Lark Health, the leading conversational-AI health coaching platform for the prevention and management of chronic conditions serving more than 2 million patients, announced today the expansion of its personalized weight management solutions to include an enhanced set of services designed to support employers and health plans through the unprecedented employee demand for GLP-1 medications.

Key Points: 
  • As part of this approach, Lark will now offer three new programs – the Healthy Weight program, GLP-1 Companion program, and Clinician-Guided Step Therapy program – all of which leverage the sustained behavior change, lifestyle management, and remote patient monitoring Lark is known for.
  • GLP-1 Companion Program is our comprehensive support program for those taking GLP-1 medications.
  • In addition to coaching on lifestyle modification, the program includes side effect management, medication adherence support, and clinical escalations as necessary.
  • Clinician-Guided Step Therapy is our program to provide access to end-to-end clinician-led therapy, offering insurance navigation, prescription management, lab monitoring, and ongoing management to ensure continuity of care.

Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD

Retrieved on: 
Monday, September 11, 2023
Psych, Cingulata, ADHD, Meta-analysis, Hour, Congress, Plasma, Insomnia, Attention deficit hyperactivity disorder predominantly inattentive, Scores, Patient, Physician, Behavioral medicine, Psychiatry, Adolescence, FDA, Recurrence, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Precision Time Protocol Industry Profile, Food, Safety, Medical imaging, Pharmaceutical industry, Dietary supplement

KANSAS CITY, Kan., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced full results from the Phase 3 adult efficacy and safety study of its lead candidate, CTx-1301 (dexmethylphenidate), for the treatment of attention deficit/hyperactivity disorder (ADHD), presented on September 8th at the 36th Annual Psych Congress, in Nashville, TN. A poster describing this data was selected as a finalist for the Psych Congress’s First Annual Poster Awards.

Key Points: 
  • A poster describing this data was selected as a finalist for the Psych Congress’s First Annual Poster Awards.
  • The Phase 3 CTx-1301-022 study ( NCT05631626 ) assessed efficacy and safety along with onset and duration of CTx-1301 in 21 adults (age range: 18-55 years) with ADHD in an adult laboratory classroom setting.
  • “Along with a restricted duration of efficacy, another limitation of current stimulant-based treatments for ADHD is the phenomena of crash and rebound they produce.
  • Additionally, CTx-1301 demonstrated a reduction in Adult ADHD Investigator Symptom Rating Scale (AISRS) scores (-16.3).

Supernus Announces New Qelbree® Data Showing Improvement in ADHD Symptoms

Retrieved on: 
Sunday, September 10, 2023
Blood pressure, Psych, MAOI, Fatigue, Research and development, Central nervous system, Depression, Senior, AE, Mania, State University of New York Upstate Medical University, Xerostomia, Aes, ADHD, Trae tha Truth, Constipation, Medicine, Appetite, CNS, OLE, AISRS, Vomiting, Administration, Insomnia, Vital signs, Patient, Child, Boxed warning, Psychiatry, Theophylline, Nausea, Somnolence, Behavioral medicine, Heart rate, Upper respiratory tract infection, FDA, Headache, Function (mathematics), Irritability, Bipolar disorder, Food, Safety, Dietary supplement, Birth control, Pharmaceutical industry, Copper, Residential care, Viloxazine

Results showed significant symptom improvement from baseline ADHD-RS-5 and CGI-S scores following both morning and evening dosing of Qelbree in combination with the morning psychostimulant.

Key Points: 
  • Results showed significant symptom improvement from baseline ADHD-RS-5 and CGI-S scores following both morning and evening dosing of Qelbree in combination with the morning psychostimulant.
  • “These data demonstrate Qelbree’s ability to enhance efficacy when co-administered with stimulants, including significant improvement during evening hours when the effects of stimulants often wear off following their morning dose.
  • Patients ADHD symptoms improved from 37.9 (6.34) to 19.7 (12.16) on the Adult ADHD Investigator Symptom Rating Scale (AISRS), representing average symptom reduction of -18.2 (11.54).
  • Patients executive function improved from 70.4 (10.94) to 58.3 (16.19) on the BRIEF-A Global Executive Composite scale, representing improvement in executive function of -12.9 (13.48).